Active, not recruitingNCT06747572
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Studying Autosomal dominant polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Enrollment
- 401 enrolled
- Eligibility
- 12-65 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Alabama Kidney Research, Alabaster, Alabama, United States
- University of Alabama at Birmingham- Nephrology Research Clinic, Birmingham, Alabama, United States
- Kaiser Permanente - Los Angeles Medical Center, Los Angeles, California, United States
- UCLA Division of Nephrology, Los Angeles, California, United States
- Helen Diller Medical Center at Parnassus Heights, San Francisco, California, United States
- Nephrology & Hypertension Associates, PC, Middlebury, Connecticut, United States
- Yale Nephrology Clinical Research Clinic, New Haven, Connecticut, United States
- Nature Coast Clinical Research - Inverness, Inverness, Florida, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Emory School of Medicine - Renal Division, Atlanta, Georgia, United States
- Renal Associates, LLC, Columbus, Georgia, United States
- UChicago Medicine - Duchossois Center for Advanced Medicine - Nephrology, Chicago, Illinois, United States
- University of Iowa Health Care Medical Center- Nephrology, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- General Clinical Research Center, University of Maryland Baltimore, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06747572 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07454174Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRichard Fatica
- RECRUITINGPHASE2NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07228364Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseAstraZeneca
- RECRUITINGNCT06970028Somatosensory Phenotyping of ADPKDUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT07260071Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseKing's College London
- ACTIVE NOT RECRUITINGNCT07016282Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational StudyMario Negri Institute for Pharmacological Research
- RECRUITINGPHASE2NCT06902558A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)AbbVie
- RECRUITINGPHASE1NCT06714006Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003PYC Therapeutics
See all trials for Autosomal dominant polycystic kidney disease →